Supporting HIV care through education and innovation

AETC ShareSpot: ACTG 5257 1st Line Therapy Study

AETC ShareSpot: ACTG 5257 1st Line Therapy Study

Thursday, May 8, 2014
AETC National Resource Center

Dr. Susa CoffeyRead a summary of results from ACTG 5257, a comparative study of 3 antiretroviral regimens, each using a fixed-dose tenofovir/emtricitabine with one of the following: Atazanavir, Raltegravir, or Darunavir.  Read the summary in the April 28 AETC ShareSpot, First-Line Therapy: Raltegravir, Darunavir, or Atazanavir?, by the AETC NRC's Dr. Susa Coffey, with this Clinical Bottom Line:

"This study provides a welcome comparison of 3 standard regimens for initial HIV therapy (each is recommended by current DHHS and IAS-USA guidelines). As expected, each performed well in terms of virologic efficacy; that is, each ART regimen worked well for those able to take and tolerate it. However, the 3 regimens were differentiated by tolerability and resistance issues."

Add a Comment

Log in or register to post comments